Jasper Therapeutics Inc. (NASDAQ:JSPR) marked $1.65 per share on Tuesday, down from a previous closing price of $1.79. While Jasper Therapeutics Inc. has underperformed by -7.82%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, JSPR fell by -51.61%, with highs and lows ranging from $4.62 to $0.39, whereas the simple moving average jumped by 11.66% in the last 200 days.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
On February 28, 2022, Cantor Fitzgerald started tracking Jasper Therapeutics Inc. (NASDAQ: JSPR) recommending Overweight. A report published by Credit Suisse on November 08, 2021, Initiated its previous ‘Outperform’ rating for JSPR. BMO Capital Markets Initiated an Outperform rating on October 20, 2021, and assigned a price target of $19. Oppenheimer initiated its ‘Outperform’ rating for JSPR, as published in its report on October 13, 2021.
Analysis of Jasper Therapeutics Inc. (JSPR)
In order to gain a clear picture of Jasper Therapeutics Inc.’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -71.60% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.90, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 2.97M can be a very valuable indicator of volatility for JSPR stock. On a monthly basis, the volatility of the stock is set at 8.23%, whereas on a weekly basis, it is put at 5.33%, with a loss of -12.70% over the past seven days. Furthermore, long-term investors anticipate a median target price of $6.21, showing growth from the present price of $1.65, which can serve as yet another indication of whether JSPR is worth investing in or should be passed over.
How Do You Analyze Jasper Therapeutics Inc. Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 5.90%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 61.50% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in JSPR shares?
The recent increase in stakes in JSPR appears to be a result of several institutional investors and hedge funds increasing their positions. The company now owns 9,900,000 shares of the stock, with a value of $19.11 million, following the purchase of 9,900,000 additional shares during the last quarter. Velan Capital Investment Manageme made another increased to its shares in JSPR during the first quarter, upping its stake by 160.48%.
JSPR shares are owned by institutional investors to the tune of 61.50% at present.
